Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
115 hedge funds and large institutions have $627M invested in Achillion Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 20 closing their positions.
320% more call options, than puts
Call options by funds: $73.8M | Put options by funds: $17.6M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
142% more capital invested
Capital invested by funds: $259M → $627M (+$368M)
105% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 20
22% more funds holding
Funds holding: 94 → 115 (+21)
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
3.37% more ownership
Funds ownership: 81.37% → 84.74% (+3.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$23.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.7M |
| 3 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$8.96M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.84M |
| 5 |
Millennium Management
New York
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$21.2M |
| 2 |
QF
QVT Financial
New York
|
-$13.7M |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$4.71M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.51M |
| 5 |
BC
Broadfin Capital
New York
|
-$3.29M |
ACHN Hedge Fund Activity: Q2 2014 in Review
115 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2014, worth a combined $627M — up 142% from $259M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ACHN positions and 20 closed out — a net gain of 21 holders — while 32 added to existing stakes and 29 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $23.1M. The largest seller was State Street, cutting an estimated $21.2M.
- 115 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2014, up from 94 in Q1 2014.
- Funds reported $627M of Achillion Pharmaceuticals stock for Q2 2014, up 142% quarter-over-quarter.
- 41 funds opened new Achillion Pharmaceuticals positions in Q2 2014 and 20 closed out, a net change of +21 holders.
- The largest Achillion Pharmaceuticals buyer in Q2 2014 was Camber Capital Management, an estimated $23.1M added.
- The largest Achillion Pharmaceuticals seller in Q2 2014 was State Street, an estimated $21.2M sold.
Based on aggregated 13F filings for Q2 2014.